Global Alzheimer’s Disease Therapeutics and Diagnostics Market 2020 Research Forecast 2026

Published On: Dec 2019

Format: PDF

Publisher: QY Research

Pages: 119

Report ID: 363880

Alzheimers is a neurodegenerative disorder that mostly occurs with aging and is a leading cause of dementia. Alzheimers is one of the leading causes of death in the United States, with more than 5 million Americans diagnosed with this dreaded disease, in year 2014.
The global Alzheimer’s Disease Therapeutics and Diagnostics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2026, growing at a CAGR of xx% during 2020-2026. The objectives of this study are to define, segment, and project the size of the Alzheimer’s Disease Therapeutics and Diagnostics market based on company, product type, end user and key regions.

This report studies the global market size of Alzheimer’s Disease Therapeutics and Diagnostics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Alzheimer’s Disease Therapeutics and Diagnostics in these regions.
This research report categorizes the global Alzheimer’s Disease Therapeutics and Diagnostics market by top players/brands, region, type and end user. This report also studies the global Alzheimer’s Disease Therapeutics and Diagnostics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
Eisai
Novartis
Forest Laboratories
TauRx Therapeutics
AC Immune
Johnson & Johnson.
H. Lundbeck

Market size by Product
Lumbar puncture test
Computed tomography (CT) scan
Magnetic resonance imaging (MRI)
Electroencephalography (EEG)
Positron emission tomography (PET) scan
Others
Market size by End User
Marketed Drugs
Pipeline Drugs

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Alzheimer’s Disease Therapeutics and Diagnostics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Alzheimer’s Disease Therapeutics and Diagnostics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Alzheimer’s Disease Therapeutics and Diagnostics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Alzheimer’s Disease Therapeutics and Diagnostics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Alzheimer’s Disease Therapeutics and Diagnostics are as follows:
History Year: 2014-2018
Base Year: 2019
Estimated Year: 2019
Forecast Year 2020 to 2026

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alzheimer’s Disease Therapeutics and Diagnostics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 Alzheimer’s Disease Therapeutics and Diagnostics Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Market Size Growth Rate by Product
1.4.2 Lumbar puncture test
1.4.3 Computed tomography (CT) scan
1.4.4 Magnetic resonance imaging (MRI)
1.4.5 Electroencephalography (EEG)
1.4.6 Positron emission tomography (PET) scan
1.4.7 Others
1.5 Market by End User
1.5.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Market Size Growth Rate by End User
1.5.2 Marketed Drugs
1.5.3 Pipeline Drugs
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Market Size
2.1.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Revenue 2015-2026
2.1.2 Global Alzheimer’s Disease Therapeutics and Diagnostics Sales 2015-2026
2.2 Alzheimer’s Disease Therapeutics and Diagnostics Growth Rate by Regions
2.2.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Sales by Regions
2.2.2 Global Alzheimer’s Disease Therapeutics and Diagnostics Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Alzheimer’s Disease Therapeutics and Diagnostics Sales by Manufacturers
3.1.1 Alzheimer’s Disease Therapeutics and Diagnostics Sales by Manufacturers
3.1.2 Alzheimer’s Disease Therapeutics and Diagnostics Sales Market Share by Manufacturers
3.1.3 Global Alzheimer’s Disease Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.2 Alzheimer’s Disease Therapeutics and Diagnostics Revenue by Manufacturers
3.2.1 Alzheimer’s Disease Therapeutics and Diagnostics Revenue by Manufacturers (2015-2020)
3.2.2 Alzheimer’s Disease Therapeutics and Diagnostics Revenue Share by Manufacturers (2015-2020)
3.3 Alzheimer’s Disease Therapeutics and Diagnostics Price by Manufacturers
3.4 Alzheimer’s Disease Therapeutics and Diagnostics Manufacturing Base Distribution, Product Types
3.4.1 Alzheimer’s Disease Therapeutics and Diagnostics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Alzheimer’s Disease Therapeutics and Diagnostics Product Type
3.4.3 Date of International Manufacturers Enter into Alzheimer’s Disease Therapeutics and Diagnostics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Sales by Product
4.2 Global Alzheimer’s Disease Therapeutics and Diagnostics Revenue by Product
4.3 Alzheimer’s Disease Therapeutics and Diagnostics Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Alzheimer’s Disease Therapeutics and Diagnostics Breakdown Data by End User

6 North America
6.1 North America Alzheimer’s Disease Therapeutics and Diagnostics by Countries
6.1.1 North America Alzheimer’s Disease Therapeutics and Diagnostics Sales by Countries
6.1.2 North America Alzheimer’s Disease Therapeutics and Diagnostics Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Alzheimer’s Disease Therapeutics and Diagnostics by Product
6.3 North America Alzheimer’s Disease Therapeutics and Diagnostics by End User

7 Europe
7.1 Europe Alzheimer’s Disease Therapeutics and Diagnostics by Countries
7.1.1 Europe Alzheimer’s Disease Therapeutics and Diagnostics Sales by Countries
7.1.2 Europe Alzheimer’s Disease Therapeutics and Diagnostics Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Alzheimer’s Disease Therapeutics and Diagnostics by Product
7.3 Europe Alzheimer’s Disease Therapeutics and Diagnostics by End User

8 Asia Pacific
8.1 Asia Pacific Alzheimer’s Disease Therapeutics and Diagnostics by Countries
8.1.1 Asia Pacific Alzheimer’s Disease Therapeutics and Diagnostics Sales by Countries
8.1.2 Asia Pacific Alzheimer’s Disease Therapeutics and Diagnostics Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Alzheimer’s Disease Therapeutics and Diagnostics by Product
8.3 Asia Pacific Alzheimer’s Disease Therapeutics and Diagnostics by End User

9 Central & South America
9.1 Central & South America Alzheimer’s Disease Therapeutics and Diagnostics by Countries
9.1.1 Central & South America Alzheimer’s Disease Therapeutics and Diagnostics Sales by Countries
9.1.2 Central & South America Alzheimer’s Disease Therapeutics and Diagnostics Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Alzheimer’s Disease Therapeutics and Diagnostics by Product
9.3 Central & South America Alzheimer’s Disease Therapeutics and Diagnostics by End User

10 Middle East and Africa
10.1 Middle East and Africa Alzheimer’s Disease Therapeutics and Diagnostics by Countries
10.1.1 Middle East and Africa Alzheimer’s Disease Therapeutics and Diagnostics Sales by Countries
10.1.2 Middle East and Africa Alzheimer’s Disease Therapeutics and Diagnostics Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Alzheimer’s Disease Therapeutics and Diagnostics by Product
10.3 Middle East and Africa Alzheimer’s Disease Therapeutics and Diagnostics by End User

11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Company Business Overview
11.1.3 Pfizer Alzheimer’s Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Pfizer Alzheimer’s Disease Therapeutics and Diagnostics Products Offered
11.1.5 Pfizer Recent Development
11.2 Eisai
11.2.1 Eisai Company Details
11.2.2 Company Business Overview
11.2.3 Eisai Alzheimer’s Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Eisai Alzheimer’s Disease Therapeutics and Diagnostics Products Offered
11.2.5 Eisai Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Company Business Overview
11.3.3 Novartis Alzheimer’s Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Novartis Alzheimer’s Disease Therapeutics and Diagnostics Products Offered
11.3.5 Novartis Recent Development
11.4 Forest Laboratories
11.4.1 Forest Laboratories Company Details
11.4.2 Company Business Overview
11.4.3 Forest Laboratories Alzheimer’s Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Forest Laboratories Alzheimer’s Disease Therapeutics and Diagnostics Products Offered
11.4.5 Forest Laboratories Recent Development
11.5 TauRx Therapeutics
11.5.1 TauRx Therapeutics Company Details
11.5.2 Company Business Overview
11.5.3 TauRx Therapeutics Alzheimer’s Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2015-2020)
11.5.4 TauRx Therapeutics Alzheimer’s Disease Therapeutics and Diagnostics Products Offered
11.5.5 TauRx Therapeutics Recent Development
11.6 AC Immune
11.6.1 AC Immune Company Details
11.6.2 Company Business Overview
11.6.3 AC Immune Alzheimer’s Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2015-2020)
11.6.4 AC Immune Alzheimer’s Disease Therapeutics and Diagnostics Products Offered
11.6.5 AC Immune Recent Development
11.7 Johnson & Johnson.
11.7.1 Johnson & Johnson. Company Details
11.7.2 Company Business Overview
11.7.3 Johnson & Johnson. Alzheimer’s Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Johnson & Johnson. Alzheimer’s Disease Therapeutics and Diagnostics Products Offered
11.7.5 Johnson & Johnson. Recent Development
11.8 H. Lundbeck
11.8.1 H. Lundbeck Company Details
11.8.2 Company Business Overview
11.8.3 H. Lundbeck Alzheimer’s Disease Therapeutics and Diagnostics Sales, Revenue and Gross Margin (2015-2020)
11.8.4 H. Lundbeck Alzheimer’s Disease Therapeutics and Diagnostics Products Offered
11.8.5 H. Lundbeck Recent Development

12 Future Forecast
12.1 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast by Regions
12.1.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Sales Forecast by Regions 2019-2025
12.1.2 Global Alzheimer’s Disease Therapeutics and Diagnostics Revenue Forecast by Regions 2019-2025
12.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast by Product
12.2.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Sales Forecast by Product 2019-2025
12.2.2 Global Alzheimer’s Disease Therapeutics and Diagnostics Revenue Forecast by Product 2019-2025
12.3 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast by End User
12.4 North America Alzheimer’s Disease Therapeutics and Diagnostics Forecast
12.5 Europe Alzheimer’s Disease Therapeutics and Diagnostics Forecast
12.6 Asia Pacific Alzheimer’s Disease Therapeutics and Diagnostics Forecast
12.7 Central & South America Alzheimer’s Disease Therapeutics and Diagnostics Forecast
12.8 Middle East and Africa Alzheimer’s Disease Therapeutics and Diagnostics Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Alzheimer’s Disease Therapeutics and Diagnostics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer